Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Total Current Liabilities (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Total Current Liabilities for 11 consecutive years, with $36.1 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities changed N/A to $36.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $36.1 million through Dec 2025, changed N/A year-over-year, with the annual reading at $36.1 million for FY2025, N/A changed from the prior year.
  • Total Current Liabilities for Q4 2025 was $36.1 million at Crescent Biopharma, up from $20.3 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $36.1 million in Q4 2025, with the low at $2.6 million in Q1 2025.
  • Average Total Current Liabilities over 5 years is $10.4 million, with a median of $8.9 million recorded in 2022.
  • Peak annual rise in Total Current Liabilities hit 369.8% in 2025, while the deepest fall reached 50.57% in 2025.
  • Over 5 years, Total Current Liabilities stood at $11.8 million in 2021, then dropped by 24.89% to $8.9 million in 2022, then decreased by 23.03% to $6.8 million in 2023, then tumbled by 36.77% to $4.3 million in 2024, then skyrocketed by 734.64% to $36.1 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $36.1 million, $20.3 million, and $16.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.